An intelligent exercise machine for measurable and motivational neuro-muscular rehabilitation therapy

Informations projet

Enjoint

N° de convention de subvention: 836465

DOI

10.3030/836465

Projet clôturé

Date de signature de la CE 4 Decembre 2018

Date de début 1 Novembre 2018

Date de fin 28 Février 2019

Financé au titre de

• INDUSTRIAL LEADERSHIP - Innovation In SMEs

Coût total

€ 71 429,00

Contribution de l’UE

€ 50 000,00

Coordonné par

ROBOFIT APS
Denmark

Periodic Reporting for period 1 - Enjoint (An intelligent exercise machine for measurable and motivational neuro-muscular rehabilitation therapy)

Période du rapport: 2018-11-01 au 2019-02-28

Résumé du contexte et des objectifs généraux du projet

Nowadays, around 13% of the European population in working age undergo some type of motor-related disfunction that requires physical rehabilitation. This percentage is expected to rise due to aging of the population and an increasing prevalence of disabling diseases.
Current rehabilitation devices fail to provide an effective therapy because of the lack of tailored training according to the patient’s needs, low self-training compliance and the lack of precise data about patient’s evolution.
At Robofit ApS (2013, Denmark) we have developed Enjoint, a novel intelligent exercise machine for neuro-muscular therapy. By using Big Data and Cloud Connection, Enjoint provides precise data about patient’s progress while adjusting the training according to the patient’s needs. Furthermore, Enjoint increases compliance of the rehabilitation program up to 87.5%, by increasing patient’s self-motivation.
Enjoint has proven to reduce session costs up to €335/patient, reaching savings of €35,000/patient/year by reducing the sick leave period. Moreover, Enjoint has a low price compared to similar products in the market.
We will start the commercialization of Enjoint by 2021 in Denmark and we expect to internationalize our customer base entering by 2022 onwards across Belgium, Germany, The Netherlands, Sweden, Austria, Spain, France, Switzerland, Croatia, Czech Republic, Hungary and Italy. Expected gross profits after 4 years of commercial exploitation are estimated at €2.8 Million.

Travail effectué depuis le début du projet jusqu’à la fin de la période considérée dans le rapport et principaux résultats atteints jusqu’à présent

First, we have carefully analyzed the market and considered a wide variety of factors, to ensure a successful production and commercialization of Enjoint. Also, we have analyzed technical improvements of our product to enable a better rehabilitation system, in line with the European policies that regulates the commercialization of this type of devices.

Progrès au-delà de l’état des connaissances et impact potentiel prévu (y compris l’impact socio-économique et les conséquences sociétales plus larges du projet jusqu’à présent)

- The project is technically feasible, and we have the required technical and commercial experience, as well as key alliances to develop it.
- The project is commercially feasible and there is a growing market for our product. Enjoint can be positioned between the global robotic rehabilitation and assistive technologies market, which is projected to attain a value of USD 2.3 billion in 2025, and the global rehabilitation equipment and devices market, which is expected to arrive at a value of USD 15.83 billion in 2025.
- The project is economically feasible and highly profitable. We estimate gross profits of around €2,8 million after 4 years of commercialization.

image-1.png